TW-37

Item no.	HY-12020-50mg
Manufacturer	MedChem Express
CASRN	877877-35-5
Amount	50 mg
Quantity options	10 mM/1 mL 10 mg 50 mg 5 mg
Category	Oncology Cardiovascular Research Ischemia & Reperfusion Injury Inhibitors & Compound Libraries Small Molecules By Organ Skin Cancer Colorectal Cancer Heart & Blood Cancer
Type	Inhibitors
Specific against	other
Purity	99.27
Citations	[1]Zeitlin BD, et al. Antiangiogenic effect of TW37, a small-molecule inhibitor of Bcl-2. Cancer Res. 2006 Sep 1;66(17):8698-706.\|[2]Mohammad RM, et al. Preclinical studies of TW-37, a new nonpeptidic small-molecule inhibitor of Bcl-2, in diffuse large cell lymphoma xenograft model reveal drug action on both Bcl-2 and Mcl-1. Clin Cancer Res. 2007 Apr 1;13(7):2226-35.
Smiles	O=C(C1=CC(CC2=CC=CC=C2C(C)C)=C(C(O)=C1O)O)NC3=CC=C(C=C3)S(=O)(C4=CC=CC=C4C(C)(C)C)=O
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	877877-35-5
Shipping Condition	Room temperature
Available
Manufacturer - Type	Reference compound
Manufacturer - Applications	Cancer-programmed cell death
Manufacturer - Targets	Bcl-2 Family
Shipping Temperature	Room Temperature
Storage Conditions	-20°C, 3 years; 4°C, 2 years (Powder)
Molecular Weight	573.70
Product Description	TW-37 is a potent Bcl-2 inhibitor with Ki values of 260, 290 and 1110 nM for Mcl-1, Bcl-2 and Bcl-xL, respectively.
Manufacturer - Research Area	Cancer
Solubility	DMSO: ≥ 42 mg/mL
Manufacturer - Pathway	Apoptosis
Isoform	Bcl-2; Bcl-xL; Mcl-1
Clinical information	No Development Reported

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-12020-50mg-safety-datasheet.pdf